Comparison of Inovio Pharmaceuticals (NASDAQ:INO) and Silk Road Medical (NASDAQ:SILK)


Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) and Silk Road Medical (NASDAQ:SILK – Get Rating) are both small medical companies, but which is the better stock? We’ll compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership, and risk.

risk and volatility

Inovio Pharmaceuticals has a beta of 0.8, suggesting its stock price is 20% less volatile than the S&P 500. In comparison, Silk Road Medical has a beta of 1.59, suggesting its stock price is 59% is more volatile than the S&P 500.

Institutional and Insider Ownership

43.3% of Inovio Pharmaceuticals shares are held by institutional investors. 3.3% of Inovio Pharmaceuticals shares are held by insiders. In comparison, 7.7% of Silk Road Medical’s shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds, and large wealth managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of the current ratings and price targets for Inovio Pharmaceuticals and Silk Road Medical as provided by

sell reviews keep ratings Buy reviews Strong buy recommendations rating score
Inovio Pharmaceuticals 0 5 0 0 2.00
Silk Road medicine 0 2 3 0 2.60

Inovio Pharmaceuticals currently has a consensus price target of $11.80, indicating a potential upside of 527.66%. Silk Road Medical has a consensus price target of $50.00, indicating a potential upside of 73.37%. Given Inovio Pharmaceuticals’ potential upside potential, analysts clearly believe Inovio Pharmaceuticals is cheaper than Silk Road Medical.

Rating & Result

This table compares the revenue, earnings per share (EPS) and valuation of Inovio Pharmaceuticals and Silk Road Medical.

gross receipts price/sales ratio net income earnings per share price-earnings ratio
Inovio Pharmaceuticals $1.77 million 243.28 -$303.66 million ($1.54) -1.22
Silk Road medicine $101.47 million 9.98 -$49.81 million ($1.61) -17.91

Silk Road Medical has higher sales and earnings than Inovio Pharmaceuticals. Silk Road Medical is trading at a lower price-to-earnings multiple than Inovio Pharmaceuticals, suggesting it’s the cheaper of the two stocks at the moment.


This table compares the net margins, return on equity and return on assets for Inovio Pharmaceuticals and Silk Road Medical.

net margins return on equity return on investment
Inovio Pharmaceuticals -20,479.29% -76.48% -63.47%
Silk Road medicine -51.93% -67.38% -35.24%


Silk Road Medical beats Inovio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Inovio Pharmaceuticals company profile (received rating)

Inovio Pharmaceuticals, Inc., a biotechnology company, is focused on the discovery, development and commercialization of DNA drugs to treat and protect people from human papillomavirus (HPV)-related diseases, cancer and infectious diseases. Its DNA drug platform uses precisely engineered SynCon that identifies and optimizes the DNA sequence of the target antigen and CELLECTRA Smart Devices technology that facilitates the delivery of the DNA plasmids. The Company is engaged in conducting and planning clinical trials of its DNA medicines for HPV-associated pre-cancers, including cervical, vulvar and anal dysplasia; HPV-associated cancers such as head and neck, cervical, anal, penile, vulva, and vaginal cancer; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East respiratory syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense ( DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research and The Wistar Institute. The Company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the investigational DNA vaccine INO-4800 for COVID-19; and a partnership with the International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Company Profile of Silk Road Medical (received rating)

Silk Road Medical logoSilk Road Medical, Inc. operates as a medical device company in the United States. The Company offers various products for the treatment of carotid artery disease known as carotid artery revascularization. Its products include the ENROUTE Transcarotid Neuroprotection System, used to directly access the common carotid artery and initiate a temporary reversal of blood flow; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in initial access to the common carotid artery; and ENROUTE .014 guidewire to navigate and traverse the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.

Receive daily news and reviews for Inovio Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inovio Pharmaceuticals and related companies with’s FREE daily email newsletter.


Comments are closed.